A Multi-Center Study Evaluating the Safety of AC-170 0.24%

Completed · Phase 3

Conditions studied: Atopic Disease (Including Allergic Conjunctivitis)

In brief

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

Key facts

Study ID

NCT02132169

Run by

Aciex Therapeutics, Inc.

People needed

512

Starts

2014-05-01

Expected to finish

2014-10-01

Last updated by the study team

2017-09-11

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• at least 2 years of age
• be able to self-administer eye drops or have a parent/legal guardian available for this purpose
• if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)
• have ocular health within normal limits

You may not qualify if…

• known contraindications or sensitivities to the study medication or its components
• any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
• use of disallowed medication during the period indicated prior to the enrollment or during the study

Where it is running

• Ora, Inc. — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.